What Is GLOW Peptide Blend?
GLOW combines three peptides: GHK-Cu + BPC-157 + TB-500. The two vials shown here contain a freeze-dried blend; the autoinjector is supplied as a preloaded solution.123
GHK-Cu
Copper tripeptide
The copper-containing component
BPC-157
15-amino-acid peptide
The second component
TB-500
Thymosin β4
Full-length in the supplied vial COAs
The 50 mg and 70 mg vials use different ingredient proportions. Both contain 10 mg of TB-500; the 70 mg vial contains more GHK-Cu and BPC-157. The pen is a separate liquid format, labeled 50 mg/mL in a 3 mL device.
GLOW 50 mg vial
GLOW 70 mg vial
Preloaded autoinjector
GLOW 50 mg vs 70 mg: What Is Inside?
The ingredient amounts below come from the supplied lot certificates. They describe two distinct formulas, not simply different pack sizes of an identical ratio.12
Ingredient amounts per vial
GLOW Blend 50 mg
35 mg GHK-Cu, 5 mg BPC-157 and 10 mg TB-500 in a 3 mL vial. The supplied certificate for lot PL-2609-042 reports 99.70% blend purity by RP-HPLC and identifies all three components by LC-MS.
GLOW Blend 70 mg
50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 in a 3 mL vial. The supplied certificate for lot PL-2609-043 reports 99.72% blend purity by RP-HPLC and identifies all three components by LC-MS.
What changes between the two vials?
The 70 mg vial adds 15 mg of GHK-Cu and 5 mg of BPC-157 compared with the 50 mg vial. The declared TB-500 amount stays at 10 mg. Choose the formulation that matches your research specification, rather than treating the two ratios as interchangeable.
Both certificates identify TB-500 as N-acetyl thymosin β4, a full-length 43-residue peptide. The supplied autoinjector specification lists 107 mg GHK-Cu, 21.4 mg BPC-157 and 21.4 mg TB-500 (Thymosin β4) per 3 mL pen, using the 5:1:1 mass ratio of the 70 mg vial.
Compare the formats and open the matching product.
GLOW Peptide Benefits: The Research Behind the Blend
Skin and collagen biology, tissue-repair mechanisms, and thymosin β4 research explain the interest in GLOW's components. Here is what the cited studies actually examine.
Skin & collagen
A fibroblast-culture study reported increased collagen synthesis with GHK-Cu. It studied the component in cells, not the complete GLOW blend.
Evidence: laboratory study 4Tissue-repair mechanisms
Tendon-explant and cell experiments examined outgrowth, survival under stress, and migration. These are experimental findings, not promised recovery outcomes.
Evidence: tissue and cell work 5Ingredient-specific evidence
A phase I study examined a recombinant thymosin β4 preparation. It did not evaluate these GLOW products or prove blend effectiveness.
Evidence: different preparation 6Component evidence is not blend evidence. These graphics describe research areas, not established treatment benefits or guaranteed results from the three products.
How to interpret the benefit claims
Collagen synthesis in a cell model, tendon-cell migration, and a phase I safety study answer different questions. None is a before-and-after trial of the 50 mg vial, the 70 mg vial, or the autoinjector shown here. The full review separates the substance studied, the method, and the outcome.
A claim of synergy also needs evidence about the combination itself. Adding ingredients or increasing a vial's total weight does not, by itself, demonstrate stronger effects. Use the formulation table to compare the products and the research page to assess the supporting studies.
Choose Your GLOW: 50 mg, 70 mg or Autoinjector
Compare all three products in one place.
GLOW Blend 50 mg
LYOPHILIZED / 3 mL VIALThe 35 / 5 / 10 mg formula.
- GHK-Cu
- 35 mg
- BPC-157
- 5 mg
- TB-500
- 10 mg
GLOW Blend 70 mg
LYOPHILIZED / 3 mL VIALThe 50 / 10 / 10 mg formula.
- GHK-Cu
- 50 mg
- BPC-157
- 10 mg
- TB-500
- 10 mg
GLOW Autoinjector
PRELOADED / 3 mL DEVICEThe ready-filled solution format.
- GHK-Cu
- 107 mg
- BPC-157
- 21.4 mg
- TB-500 (Thymosin β4)
- 21.4 mg
Prefer a powder vial? Compare the ingredient amounts and choose the 50 mg or 70 mg formulation required for your work. Need the preloaded format? The 3 mL autoinjector contains GHK-Cu 107 mg, BPC-157 21.4 mg and TB-500 (Thymosin β4) 21.4 mg.
For the vials, 3 mL describes container capacity, not a supplied liquid volume. For the pen, 3 mL is the stated solution fill. Product facts: supplied vial certificates and autoinjector product record.123
GLOW Peptide Before and After: Reading the Evidence
Before-and-after claims should identify the exact product, what changed, how the outcome was measured, and what else happened during the same period. Lighting, skincare, camera position and other treatments can affect the apparent result. A review of delivery or packaging is not evidence of a biological effect.
How long does GLOW take to work?
PLACE HOLDER TEXT
Explore the GLOW before-and-after page →GLOW Peptide Dosage: Know the Format First
The two vial labels state total contents; the pen label states concentration and fill volume. A 50 mg vial is therefore not the same quantity as a 50 mg/mL pen.
50 mg and 70 mg vials
50 mg vial: GHK-Cu 35 mg, BPC-157 5 mg and TB-500 10 mg.
70 mg vial: GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg.
Both are freeze-dried blends in 3 mL vials.
Preloaded autoinjector
Per 3 mL pen: GHK-Cu 107 mg, BPC-157 21.4 mg and TB-500 (Thymosin β4) 21.4 mg.
Listed concentration: 50 mg/mL total blend.
Mass ratio: 5:1:1, matching the 70 mg vial.
The supplied specification describes a sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a 3 mL glass cartridge inside a preloaded autoinjector pen fitted with a needle. Sealed storage: 2–8 °C in the original carton, protected from light. Safety data sheet: PL-SDS-070.3
PLACEHOLDER TEXT
GLOW Safety and Product Handling
The supplied vial certificates state for laboratory research use only, not for human or veterinary use. They report results for particular samples and lots; they are not clinical safety approvals.12
The vial records list sealed storage at −20 °C, desiccated and protected from light. Use the current label and supplier instructions for your exact product. Do not transfer powder-vial storage assumptions to a preloaded solution.
Testing a sample's identity, purity, endotoxin or sterility does not establish a personal dose or rule out adverse effects from use. For individual medical questions, speak with a licensed clinician. GLOW safety overview.
GLOW Testing and Batch Reports
Open the actual certificates for the 50 mg and 70 mg vials. Each report includes identity results, purity, additional tests and the chromatogram for its named lot.
GLOW Blend 50 mg
Reported area%
by LC-MS
Analysed 18 September 2026. Original supplier-issued, in-house report; not an independent third-party test.
GLOW Blend 70 mg
Reported area%
by LC-MS
Analysed 17 September 2026. Original supplier-issued, in-house report; not an independent third-party test.
The graphs above are excerpts from the supplied certificates, not recreated charts. Both reports were issued on 3 October 2026 by PrymaLab Analytical, the supplier's in-house laboratory.12
| Reported test | 50 mg · PL-2609-042 | 70 mg · PL-2609-043 |
|---|---|---|
| LC-MS identity | 3/3 components confirmed | 3/3 components confirmed |
| RP-HPLC purity | 99.70% | 99.72% |
| Water content | 2.0% | 2.0% |
| Bacterial endotoxin | 0.05 EU/mg | 0.05 EU/mg |
| Sterility / bioburden | No growth; conforms | No growth; conforms |
| Overall conclusion | PASS for tests performed | PASS for tests performed |
See the record, not just a purity badge.
The original PDFs include the laboratory identity, batch, methods, chromatogram, mass-spectrometry information and approval fields. Open the document to review its full scope. Both certificates apply only to the lots they name.
Buy GLOW Blend in Your Preferred Format
Choose a 50 mg vial, a 70 mg vial or the preloaded autoinjector. Open your selected product to check current pricing, availability and purchasing conditions.
50 mg or 70 mg: compare ingredients, not just the total
The 50 mg formula supplies 35 mg GHK-Cu, 5 mg BPC-157 and 10 mg TB-500. The 70 mg formula supplies 50 mg, 10 mg and 10 mg respectively. The 20 mg difference comes from GHK-Cu and BPC-157; the TB-500 amount is unchanged.
For a vial purchase, review the formulation alongside the matching certificate and confirm the lot supplied with your order. For a pen purchase, the supplied specification lists GHK-Cu 107 mg, BPC-157 21.4 mg and TB-500 (Thymosin β4) 21.4 mg in a 3 mL fill. The pen follows the 5:1:1 mass ratio of the 70 mg vial.
What should you compare on price?
Compare the exact format, ingredient amounts, quantity of containers and total order charges. A sale price, bundle discount or shipping charge can change the comparison. Check the live product page rather than relying on a copied price in an older article.
For a more detailed comparison, visit our pricing and purchasing information. The product buttons take you to the selected format on the Buy page; purchasing and checkout remain there.
Ready to choose your GLOW?
Three product options. Ingredient details up front. Original lot reports for both vials.
Buy 50 mgBuy 70 mgBuy AutoinjectorFrequently Asked Questions About GLOW Peptide
What is in the GLOW peptide blend?
The products list GHK-Cu, BPC-157 and TB-500. The supplied vial certificates identify TB-500 as full-length thymosin β4. The ingredient split differs between the two vial formulations. GLOW formulation overview.12
What is the difference between GLOW 50 mg and 70 mg?
The 50 mg vial contains 35 mg GHK-Cu, 5 mg BPC-157 and 10 mg TB-500. The 70 mg vial contains 50 mg, 10 mg and 10 mg. The 70 mg option has 15 mg more GHK-Cu and 5 mg more BPC-157.
How much blend is in the autoinjector?
The autoinjector is labeled 50 mg/mL in a 3 mL device. The supplied specification lists GHK-Cu 107 mg, BPC-157 21.4 mg and TB-500 (Thymosin β4) 21.4 mg per pen, with 150 mg total labeled blend and a 5:1:1 mass ratio.3
Are the vial reports independent third-party tests?
No. Both supplied certificates explicitly identify the testing as in-house. The 99.70% and 99.72% figures belong to the named vial lots.
Where can I read about GLOW benefits and results?
The Benefits page discusses research on the individual components. The Before & After page explains how to assess outcome claims. Neither replaces a clinical evaluation of these finished products.
Where is the dosage information?
The Dosage page explains formulation, concentration and evidence behind protocol claims. It is not an individualized treatment or self-administration guide.
Where can I buy the three formats?
Use Buy 50 mg, Buy 70 mg or Buy Autoinjector to open the corresponding format. Check current pricing and purchasing conditions on the Buy page.
Sources and Product Documentation
- 1Supplied GLOW Blend 50 mg lot certificate
Lot PL-2609-042 / certificate PL-26-00042. Formulation and reported in-house analytical results. - 2Supplied GLOW Blend 70 mg lot certificate
Lot PL-2609-043 / certificate PL-26-00043. Formulation and reported in-house analytical results. - 3Autoinjector product specification
Supplied manufacturer specification: 3 mL at 50 mg/mL; GHK-Cu 107 mg, BPC-157 21.4 mg and TB-500 (Thymosin β4) 21.4 mg. PL-SDS-070. - 4GHK-Cu fibroblast study
Maquart et al. (1988). Collagen-synthesis study in cultured fibroblasts; not a finished-blend trial. - 5BPC-157 tendon and cell study
Chang et al. (2011). Tendon-explant and fibroblast experiments; not a trial of these GLOW products. - 6Recombinant thymosin beta-4 phase I study
Wang et al. (2021). A different recombinant preparation; not evidence of efficacy for these products.
Formulation and analytical values refer to the linked product records and named lot certificates. Supplier identification remains visible on the original reports. Scientific references describe the studied ingredients and preparations, not a clinical evaluation of the finished GLOW blends.